Clinical Trials
388
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (331 trials with phase data)• Click on a phase to view related trials
Drug Use Study With Intuniv® in European Countries
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Shire
- Target Recruit Count
- 5000
- Registration Number
- NCT05870605
- Locations
- 🇩🇪
Real World Insights EMEA IQVIA Commercial GmbH & Co. OHG, Munich, Bavaria, Germany
A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using NATPARA
- Conditions
- Hypoparathyroidism
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Shire
- Target Recruit Count
- 200
- Registration Number
- NCT05556629
- Locations
- 🇺🇸
Shire-NPS Pharmaceuticals, INC. (Shire now part of Takeda), Lexington, Massachusetts, United States
A Study of Replagal in Children and Adults With Fabry Disease in India
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Shire
- Target Recruit Count
- 5
- Registration Number
- NCT05067868
- Locations
- 🇮🇳
Institute of Child Health, Kolkata, India
🇮🇳All India Institute of Medical Sciences (AIIMS), New Delhi, India
🇮🇳Sir Gangaram Hospital, New Delhi, India
Drug Use Study With VYVANSE® in Australia for Binge Eating Disorder
- Conditions
- Binge-eating Disorder
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- Shire
- Target Recruit Count
- 150
- Registration Number
- NCT04866043
- Locations
- 🇦🇺
Site, Sydney, New South Wales, Australia
Drug Use Study With Intuniv® in Australia
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- First Posted Date
- 2021-04-29
- Last Posted Date
- 2021-10-04
- Lead Sponsor
- Shire
- Target Recruit Count
- 100
- Registration Number
- NCT04866030
- Locations
- 🇦🇺
Site, Sydney, New South Wales, Australia
- Prev
- 1
- 2
- 3
- 4
- 5
- 71
- Next
News
CMV Treatment Pipeline Expands with 20+ Therapies from Leading Pharmaceutical Companies
DelveInsight's 2025 assessment reveals 15+ companies are developing over 20 cytomegalovirus (CMV) infection treatment therapies across various clinical development phases.
Takeda Accelerates US Investment Strategy While Advancing Three Pivotal Phase III Programs for 2025
Takeda Pharmaceutical is planning significant investments in US operations while reporting minimal anticipated impact from recent tariff policies on their global business strategy.
Walden Biosciences Strengthens Board with Appointment of Rare Disease Expert Howard Mayer
Walden Biosciences has appointed Howard Mayer, M.D., former Executive VP of R&D at Ipsen, to its Board of Directors as the company approaches key clinical milestones.
Prucalopride Shows Broad Efficacy in Chronic Constipation Across Patient Demographics, New Analysis Reveals
Post-hoc analysis of six phase 3 and 4 clinical trials demonstrates prucalopride's effectiveness in treating chronic idiopathic constipation across different age groups, with significant improvements in bowel movements.